IP Library Granted Patent US 8,067,035
Granted Patent B2
US 8,067,035 · App. 11/614,859 · Granted Nov 29, 2011

Chlorite formulations, and methods of preparation and use thereof

Assignee: Neuraltus Pharmaceuticals, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,067,035
App. No.
11/614,859
Granted
Nov 29, 2011
Kind
B2
Abstract

Described herein are chlorite formulations having a pH between about 7 and about 8.5, wherein the chlorite formulations are substantially free of deleterious non-chlorite components. Described herein are chlorite formulations, including pharmaceutical formulations, which are formulated for systemic, parenteral, or intravenous administration. Described herein are methods of preparing and methods of using the chlorite formulations described herein.

Claims (26)

1. A pharmaceutical composition comprising:

(a) an aqueous solution comprising sodium chlorite, wherein the weight ratio of chlorite:chlorate is greater than 100:1.5, and the concentration of chlorite is at 60 mM;

(b) a phosphate buffer; and

(c) a pharmaceutically acceptable excipient;

wherein the composition is a sterile intravenous solution having a pH between about 7 and about 9.5.

2. A unit dose form of a formulation, wherein the unit dose form comprises an effective amount of a pharmaceutical composition comprising:

(a) an aqueous solution comprising sodium chlorite, wherein the weight ratio of chlorite:chlorate is greater than 100:1.5, and the concentration of chlorite is at least 60 mM;

(b) a phosphate buffer; and

(c) a pharmaceutically acceptable excipient;

wherein the composition is a sterile intravenous solution having a pH between about 7 and about 9.5.

3. The unit dose form of claim 2 , wherein the unit dose is ready for administration to a subject.

4. The unit dose form of claim 2 , wherein the unit dose is diluted prior to administration to a subject.

5. The unit dose form of claim 2 , wherein the pH of the composition is between about 7.1 and about 7.7.

6. The composition of claim 1 wherein the excipient comprises saline solution.

7. The composition of claim 6 wherein the saline solution is isotonic.

8. The composition of claim 1 comprised in flexible packaging.

9. The composition of claim 1 or 2 , wherein the concentration of chlorite is between 60 mM and about 65 mM.

10. The composition of claim 9 , wherein the concentration of chlorite is about 62 mM.

11. The composition of claim 1 or 2 , wherein the concentration of chlorite is at least 100 mM.

12. The composition of claim 1 , wherein the concentration of chlorite is between about 1 M and about 1.5 M.

13. The composition of claim 1 , wherein the weight ratio of chlorite:chlorate is greater than 100:0.5.

14. The composition of claim 1 , wherein the weight ratio of chlorite:sulfate is greater than 100:16.4.

15. The composition of claim 1 , wherein the weight ratio of chlorite:sulfate is greater than 100:1.6.

16. The composition of claim 1 , wherein sulfate comprises no more than 1 part in 1000 per weight of non-solvent molecules.

17. The composition of claim 1 , wherein the weight ratio of chlorite:chloride is greater than 100:10.

18. The composition of claim 1 , wherein the pH of the composition is between about 7.0 and 8.5.

Assignments (5)
CHANGE OF NAME Recorded Sep 10, 2021
From: NEUVIVA, INC.
To: NEUVIVO, INC.
Reel/Frame 057471/0847 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 6, 2020
From: NORVIEL, VERNON A.
To: NEUVIVA, INC.
Reel/Frame 053425/0719 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 27, 2019
From: NEURALTUS PHARMACEUTICALS, INC.
To: NORVIEL, VERNON A.
Reel/Frame 051380/0353 →
CHANGE OF NAME Recorded Jun 17, 2010
From: TAIJI BIOMEDICAL, INC.
To: NEURALTUS PHARMACEUTICALS, INC.
Reel/Frame 024554/0011 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 27, 2007
From: BOULANGER, WILLIAM; AZHIR, ARASTEH ARI
To: TAIJI BIOMEDICAL, INC.
Reel/Frame 019072/0145 →
Continuity (2)
Provisional Application 60753497 · Dec 22, 2005
Related Publication 20070145328A1 · Jun 28, 2007